B-lymfocytdepletring og andre biologiske behandlingsmuligheder ved Graves' oftalmopatiTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Fassi D. El; L. Hegedus; Claus Henrik Nielsen

B-lymfocytdepletring og andre biologiske behandlingsmuligheder ved Graves' oftalmopatiTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Fassi D. El, L. Hegedus, Claus Henrik Nielsen

1 Citation (Scopus)

Abstract

The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO
Udgivelsesdato: 2008/6/9

Original language	Danish
Journal	Ugeskrift for læger
Volume	170
Issue number	24
Pages (from-to)	2128-2130
Number of pages	2
ISSN	0041-5782
Publication status	Published - 2008

Cite this

B-lymfocytdepletring og andre biologiske behandlingsmuligheder ved Graves' oftalmopatiTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. / El, Fassi D.; Hegedus, L.; Nielsen, Claus Henrik.

In: Ugeskrift for læger, Vol. 170, No. 24, 2008, p. 2128-2130.

Research output: Contribution to journal › Journal article › Research › peer-review

El, Fassi D. ; Hegedus, L. ; Nielsen, Claus Henrik. / B-lymfocytdepletring og andre biologiske behandlingsmuligheder ved Graves' oftalmopatiTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. In: Ugeskrift for læger. 2008 ; Vol. 170, No. 24. pp. 2128-2130.

@article{98087fb0986b11de8bc9000ea68e967b,

title = "B-lymfocytdepletring og andre biologiske behandlingsmuligheder ved Graves' oftalmopatiTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease",

abstract = "The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO Udgivelsesdato: 2008/6/9",

author = "El, {Fassi D.} and L. Hegedus and Nielsen, {Claus Henrik}",

year = "2008",

language = "Dansk",

volume = "170",

pages = "2128--2130",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "24",

}

TY - JOUR

T1 - B-lymfocytdepletring og andre biologiske behandlingsmuligheder ved Graves' oftalmopatiTumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

AU - El, Fassi D.

AU - Hegedus, L.

AU - Nielsen, Claus Henrik

PY - 2008

Y1 - 2008

N2 - The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO Udgivelsesdato: 2008/6/9

AB - The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO Udgivelsesdato: 2008/6/9

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 170

SP - 2128

EP - 2130

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 24

ER -